BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35818395)

  • 1. Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer.
    Gui CP; Li JY; Fu LM; Luo CG; Zhang C; Tang YM; Zhang LZ; Shu GN; Wu RP; Luo JH
    J Big Data; 2022; 9(1):88. PubMed ID: 35818395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferroptosis Patterns and Tumor Microenvironment Infiltration Characterization in Bladder Cancer.
    Xia QD; Sun JX; Liu CQ; Xu JZ; An Y; Xu MY; Liu Z; Hu J; Wang SG
    Front Cell Dev Biol; 2022; 10():832892. PubMed ID: 35386202
    [No Abstract]   [Full Text] [Related]  

  • 3. A novel survival model based on a Ferroptosis-related gene signature for predicting overall survival in bladder cancer.
    Liang Y; Ye F; Xu C; Zou L; Hu Y; Hu J; Jiang H
    BMC Cancer; 2021 Aug; 21(1):943. PubMed ID: 34418989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUMOylation Pattern Predicts Prognosis and Indicates Tumor Microenvironment Infiltration Characterization in Bladder Cancer.
    Xia QD; Sun JX; Xun Y; Xiao J; Liu CQ; Xu JZ; An Y; Xu MY; Liu Z; Wang SG; Hu J
    Front Immunol; 2022; 13():864156. PubMed ID: 35418978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer.
    An Y; Sun JX; Xu MY; Xu JZ; Ma SY; Liu CQ; Liu Z; Wang SG; Xia QD
    Front Immunol; 2022; 13():1049884. PubMed ID: 36420257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
    Xu Y; Sun X; Liu G; Li H; Yu M; Zhu Y
    Front Immunol; 2023; 14():1301157. PubMed ID: 38299148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive role of ferroptosis-related long non-coding RNAs in bladder cancer and their association with immune microenvironment and immunotherapy response.
    Liu J; Zhang Z; Liu X; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
    World J Surg Oncol; 2022 Feb; 20(1):47. PubMed ID: 35209909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel signature constructed by ferroptosis-associated genes (FAGs) for the prediction of prognosis in bladder urothelial carcinoma (BLCA) and associated with immune infiltration.
    Luan JC; Zeng TY; Zhang QJ; Xia DR; Cong R; Yao LY; Song LB; Zhou X; Zhou X; Chen X; Xia JD; Song NH
    Cancer Cell Int; 2021 Aug; 21(1):414. PubMed ID: 34362387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. m
    Zhang B; Wu Q; Li B; Wang D; Wang L; Zhou YL
    Mol Cancer; 2020 Mar; 19(1):53. PubMed ID: 32164750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a Novel Ferroptosis-Related Gene Prognostic Signature in Bladder Cancer.
    Sun J; Yue W; You J; Wei X; Huang Y; Ling Z; Hou J
    Front Oncol; 2021; 11():730716. PubMed ID: 34557413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of a novel RNA modifications-related model in the prognostic characterization, immune landscape and drug therapy of bladder cancer.
    Zhang Z; Chen P; Yun J
    Front Genet; 2023; 14():1156095. PubMed ID: 37124622
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development.
    Wu C; Qin C; Long W; Wang X; Xiao K; Liu Q
    J Big Data; 2022; 9(1):92. PubMed ID: 35855914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a T cell proliferation-associated regulator signature correlates with prognosis risk and immunotherapy response in bladder cancer.
    Yan T; Zhou W; Li C
    Int Urol Nephrol; 2024 May; ():. PubMed ID: 38789872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of tumor-infiltrating lymphocyte-related prognosis signature for predicting prognosis and immunotherapeutic response in bladder cancer.
    Li C; Xie W
    BMC Bioinformatics; 2023 Mar; 24(1):118. PubMed ID: 36973645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematical analysis of ferroptosis regulators and identification of GCLM as a tumor promotor and immunological biomarker in bladder cancer.
    Wang S; Wang H; Zhu S; Li F
    Front Oncol; 2022; 12():1040892. PubMed ID: 36353567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferroptosis-related long non-coding RNA signature predicts the prognosis of bladder cancer.
    Hou J; Lu Z; Cheng X; Dong R; Jiang Y; Wu G; Qu G; Xu Y
    BMC Cancer; 2022 Jun; 22(1):719. PubMed ID: 35768833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Ferroptosis-Related lncRNA Signature to Predict the Prognosis and Immune Landscape of Bladder Cancer.
    Zhou R; Liang J; Tian H; Chen Q; Yang C; Liu C
    Dis Markers; 2021; 2021():1031906. PubMed ID: 34239619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robust Prediction of Prognosis and Immunotherapy Response for Bladder Cancer through Machine Learning Algorithm.
    Hu S; Gu S; Wang S; Qi C; Shi C; Qian F; Fan G
    Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer.
    Yang L; Li C; Qin Y; Zhang G; Zhao B; Wang Z; Huang Y; Yang Y
    Front Oncol; 2021; 11():686044. PubMed ID: 34422642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer.
    Wang Y; Chen L; Yu M; Fang Y; Qian K; Wang G; Ju L; Xiao Y; Wang X
    Cancer Med; 2020 Oct; 9(20):7729-7741. PubMed ID: 32841548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.